Sekretessinställningar
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • BlankningSe vilka börsnoterade bolag som har offentliggjorda korta positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

Transkriptioner

Läs transkriptioner från webbsändningar och audiocasts

Transkriptioner

Läs transkriptioner från webbsändningar och audiocasts

Alla regioner
Sverige
Finland
Danmark
Norge
Senaste
Trendande
Följda

Scandion Oncology, Audiocast with teleconference, Q3'24

Av Inderes2024-11-11 08:00
Scandion Oncology

Ansvarsfriskrivning: Detta är en maskin­genererad transkription och kan innehålla felaktigheter.

Francois Martelet
00:00 - 05:24

Good morning, everyone, and thank you for attending this quarterly call for 2024. Uh, could I have the next slide, please? Which is the disclaimer. The classical disclaimer is that we will not go through the next slide. So together with me, we have Johnny Stilou, our CFO, and I will quickly go through the clinical updates. Then Johnny will go through the financial performance, and then I will update you about our partnering activities. Next slide, please. Yes. All right. So you can see us. Next slide. Right. So, as most of you likely know, we are involved in Colorectal Cancer. We are a drug resistance company. One of the first companies actually in this setting. And we have, over the last few years, engaged in a program called CORIST. And, with our compound, our lead compound, SCO-101, which is a small molecule combined with FOLFIRI, we've advanced from phase one to phase two, and now we are in phase two A. We are certainly expecting the final data to be released early. In 2025, we released the top-line data, which are positive phase 2A data. And we will be releasing the final data analysis early in 2025. So, for colorectal cancer, this pertains to the CORIST program. And I will go into more details later on. PANTAX is our clinical trial in pancreatic cancer. This is a phase 1B. We have released the data earlier this year that show good tolerability, good safety with a combination of nab-paclitaxel and gemcitabine and, of course, SCO-101. At the same time, you know, we engaged earlier in gastric cancer and have been able to release some good preclinical data for this indication. Therefore, we are ready to engage in a phase 1B2A. At the same time, mainly due to cost constraints, we have not been able to continue the preclinical development program with SCO-201. But this is certainly an asset that could also potentially be used in other indications beyond oncology, like HIV, and that asset is currently on hold from a preclinical development perspective. Should I have the next slide, please? Right. So here are a bit more details about CORIST. So we've been able to release the top-line data earlier in the year. We've been able to demonstrate a good safety and tolerability profile. Something which is very important in oncology is, of course, partial responses. And in the last cohort where we've been able to demonstrate our MTD, we have got two PRs. And this is extremely encouraging for us and for the patients. Of course, at the same time, we've been able to show a significant overall survival, which is in the range of 8 to 10 months. And also, if we are selecting a subgroup of patients expressing one type of UGT1A1, then we've been able to increase the overall survival up to 13 months, which is significant. I know, of course, that this is based on a limited set of patients, but at least we have to start somewhere. And obviously, this can only be encouraging for the future development of our clinical trial. So the conclusion is that we've been able to achieve an MTD (maximum tolerated dose) for the four-day schedule using SCO-101 in combination with FOLFIRI, meaning that we have 50% oenothera dosage and 100% Leucovorin and 5-FU. And then the result is that we have an MTD at 250 mg per day of SCO-101. So altogether, this is extremely encouraging for continuing the development of our clinical development plan for colorectal cancer with SCO-101. Next slide, please. So this is for Johnny. Johnny, please go ahead.

Johnny Stilou
05:24 - 07:19

Thank you. Yes, this is the financial overview. And as you can see, the third quarter of 2024 ended with a net loss of 6.7 million Danish kroner. This is compared to the same quarter last year, where we had a net loss of 10.1 million Danish kroner. The reduction in loss and cost is driven by reduced clinical costs, as our two clinical programs have been downscaled. Our cash position at the end of September, the end of the quarter, ended with a balance of 14.8 million Danish kroner. Now, with this number. Bear in mind that we have a tax credit due of 5.5 million Danish kroner, which we receive annually due to our clinical costs, clinical programs. And this money, 5.5 million Danish kroner, we will receive for this year later in this month, in November. But as of the end of September, we had 14.8 million Danish kroner. With that cash position, we are able to fund the operation into the fourth quarter of next year, 2025. And here on the next slide, you can see graphically that our cost is being reduced quarter over quarter. And we expect the same reduction in quarter-over-quarter costs to continue into 2025, which is why, as just mentioned, our current cash position will sustain us into the fourth quarter of 2025. With that, I will hand the word back to Francois.

Francois Martelet
07:20 - 10:19

Thank you, Johnny. So, if I could summarize where we stand now. As you know, we are a drug resistance company. We are one of the first movers in this direction. And with our SCO-101, potentially we have a first-in-class drug inhibitor. And we are targeting two targets, CPG2 and UGT1A1, as you know. So we are really a precision anti-cancer drug company. We've been able to demonstrate good data from a phase 2A in colorectal cancer. Also, some good data in phase 1B in pancreatic cancer. And certainly, our compound has broad commercial potential not only in those indications but also in others that could be further developed depending on our financial position. Financially speaking, we've been able to control costs very drastically. And as Johnny said, we are able to finance the company into Q4 2025. Obviously, what's next? As most of you have understood, we are now in the middle of the development process for colorectal cancer. Having achieved good phase two. Having achieved good phase two A, so now we need to move the pipeline towards phase 2B/3. In order to do that, we certainly need additional funding, and performing a phase 2B3 in colorectal cancer requires hundreds of patients. Therefore, from a financial perspective, we need to have a partner, given the market conditions, given where we stand as a publicly listed company. A partner is absolutely needed in order to continue this development program. And this is exactly what I am focusing all my efforts on, together with Johnny and our CMO and our CSO. And on that side, I'm sure you will appreciate some confidential information that I cannot disclose, but be absolutely sure that we are doing our utmost to find a partner. And of course, we will be releasing good news whenever available. And I will not say more about that. But again, rest assured that our commitment is 100% towards these development activities. Uh, next slide please. And this will conclude our brief presentation today, and I am open to any questions you may have. Slide set today, and I am open to any questions you may have. Back to you. Operator, please.

Operator
10:21 - 10:54

Thank you. If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. We'll have a brief pause while questions are being registered. There seem to be no questions. So, I hand the word back to you, Francois and Johnny.

Francois Martelet
10:57 - 11:13

Thank you. Thank you to the audience for listening to us today on this important but short call. And again, we will be updating the market as soon as we have news on the business development side. Thank you very much. And have a good day.

Till webcasten
Pierce Group, Audiocast, Q3'26
Språk: Engelska2026-11-13 08:00
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Språk: Engelska2026-11-12 10:00
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Språk: Engelska2026-11-12 09:00
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Språk: Engelska2026-11-12 08:00
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 08:00
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Språk: Svenska2026-11-12 08:00
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 08:00
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 07:15
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Språk: Engelska2026-11-11 13:00
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Språk: Engelska2026-11-11 13:00
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Språk: Engelska2026-11-11 12:30
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Språk: Engelska2026-11-11 09:00
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Språk: Engelska2026-11-11 09:00
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Språk: Engelska2026-11-10 17:00
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Språk: Engelska2026-11-10 08:00
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Språk: Engelska2026-11-10 08:00
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Språk: Svenska2026-11-06 09:00
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…